CYP2J2 is a cytochrome P450 monooxygenase predominantly expressed in extrahepatic tissues, particularly the heart, where it catalyzes the epoxidation of polyunsaturated fatty acids (PUFA) 1. The enzyme converts arachidonic acid to epoxyeicosatrienoic acids (EETs) and related lipid mediators through a mechanism involving molecular oxygen insertion and NADPH-dependent electron transfer 2. CYP2J2 also metabolizes xenobiotics including pharmaceuticals like astemizole and terfenadine 3. The resulting epoxylipid products function as signaling mediators with cardioprotective roles and involvement in angiogenesis, hematopoiesis, and metabolic regulation 4. Clinically, CYP2J2 has emerged as a disease-relevant target in multiple contexts. Gene polymorphisms, particularly the -50G/T variant, associate with increased ischemic stroke risk in Chinese populations 5. CYP2J2 is upregulated in colorectal cancer, where Fusobacterium nucleatum-induced CYP2J2 expression promotes epithelial-mesenchymal transition and metastasis through TLR4/NRF2 signaling, correlating with worse outcomes in stage III/IV disease 6. CYP2J2 upregulation also occurs in other cancers, making selective CYP2J2 inhibitors (e.g., C26) candidates for cancer therapy 3. Additionally, CYP2J2 polymorphisms associate with hypertensive intracerebral hemorrhage risk 7. Understanding CYP2J2 regulation in disease states and designing targeted inhibitors represent promising therapeutic strategies 8.